Antibody which specifically binds to human CRTH2

Patent metadata

Field	Value
Publication number	US-9938349-B2
Application number	US-201615342534-A
Country	US
Kind code	B2
Filing date	Nov 3, 2016
Priority date	Jul 15, 2015
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

There is provided an anti-human CRTH2 antibody which has desired activity by recognizing and binding to a specific human CRTH2; the antibody fragment; DNA which encodes the amino acid sequence of the antibody; a vector which comprises the DNA; hybridomas and antibody producing cells which produce the antibody; a method of producing the antibody; a composition which comprises the antibody or the antibody fragment; a treatment method and a diagnostic method of an allergic disease, an autoimmune disease, a disease accompanied by at least one of increase and hyperergasia of eosinophils; a disease accompanied by at least one of increase and hyperergasia of Th2 cells using the antibody or the antibody fragment; and a medicine and a diagnostic agent which comprise the antibody or the antibody fragment.

First claim

The invention claimed is:

1. An antibody or an antibody fragment thereof which recognizes at least one of 192th glycine and 194th aspartic acid in the amino acid sequence of human CRTH2 of SEQ ID NO: 2 and binds thereto, wherein the antibody comprises complementarity determining regions (CDR) 1 to 3 of an antibody heavy chain variable region (VH) comprise amino acid sequences represented by SEQ ID NOS: 20 to 22, respectively, and CDRs 1 to 3 of an antibody light chain variable regions (VL) comprise amino acid sequences represented by SEQ ID NOS: 23 to 25, respectively.

2. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody comprises VH comprising the amino acid sequence represented by SEQ ID NO: 49 or the amino acid sequence obtained by introducing at least one modification selected from modifications of substituting 18th leucine with methionine, 77th asparagine with serine, 93th valine with threonine, and 117th threonine with valine in the amino acid sequence represented by SEQ ID NO: 49 and VL comprising the amino acid sequence represented by SEQ ID NO: 33 or the amino acid sequence obtained by at least one modification selected from modifications of substituting 2nd isoleucine with valine, 4th methionine with leucine, 15th proline with leucine, and 85th alanine with proline in the amino acid sequence represented by SEQ ID NO: 33.

3. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody comprises VH comprising any one of the amino acid sequences represented by SEQ ID NOS: 49, 51, 53, 55, 57, and 59 and VL comprising any one of the amino acid sequences represented by SEQ ID NOS: 33, 35, 37, 39, 41, 43, 45, and 47.

4. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody comprises a human Fc region.

5. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody is a monoclonal antibody.

6. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody is a recombinant antibody.

7. The antibody or the antibody fragment thereof according to claim 1 , wherein the antibody is an antibody which binds to monkey CRTH2.

8. The antibody fragment according to claim 1 , wherein the antibody fragment is any one selected from Fab, Fab′, F(ab′) 2 , scFv, diabody, and dsFv.

Assignees

• Kyowa Hakko Kirin Co Ltd

Inventors

• Kameyama Naoya
• Ando Munetoshi
• Ogawa Shinya
• Okada Kazuki

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• G01N2333/70596

  Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705 · CPC title